They include: Nausea Diarrhea Vomiting Constipation Decreased appetite Dysesthesia (abnormal sensations of the skin, such as burning, tingling, itching, pain, crawling, etc.) Since clinical trials are ongoing, knowledge of retatrutides side effects may change
There are no published studies on the matter
Researchers believe the bodys hunger and reward centers become more active again once the medication leaves the system
Phase 2 trials studied up to 12 mg weekly, but no approved dosing regimen exists in the UK
Second, most available trials are characterized by short follow-up periods (generally 612 months), providing limited insight into the durability of weight loss, muscle preservation, or cardiometabolic benefits after treatment cessation